Skip to main content

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SLQT, SAVA and SPPI

NEW YORK, NY / ACCESSWIRE / September 13, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Selectquote, Inc. (NYSE:SLQT)
Class Period: February 8, 2021 - May 11, 2021
Lead Plaintiff Deadline: October 15, 2021

The complaint alleges that throughout the class period Selectquote, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) SelectQuote's 2019 cohort was underperforming; (2) as a result, the Company's financial results would be adversely impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in SLQT: https://www.kleinstocklaw.com/pslra-1/selectquote-inc-loss-submission-form?id=19543&from=1

Cassava Sciences, Inc. (NASDAQ:SAVA)
Class Period: February 2, 2021 - August 24, 2021
Lead Plaintiff Deadline: October 26, 2021

Cassava Sciences, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in SAVA: https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19543&from=1

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
Class Period: December 27, 2018 - August 5, 2021
Lead Plaintiff Deadline: November 1, 2021

The SPPI lawsuit alleges that throughout the class period, Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in SPPI: https://www.kleinstocklaw.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?id=19543&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/663812/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-SLQT-SAVA-and-SPPI

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.